| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.350 | Biomarker | disease | BEFREE | We performed immunohistochemistry to detect TLE1 and β-catenin and investigated the catenin beta-1 (CTNNB1) mutational profile among BCA and BCAC cases. | 30053869 | 2018 | ||||
|
0.350 | AlteredExpression | disease | BEFREE | Nuclear β-catenin expression was present in 97.6% of BCA and 66.7% of BCAC cases but not in AdCC cases. | 29224720 | 2018 | ||||
|
0.350 | Biomarker | disease | BEFREE | We performed immunohistochemical staining for β-catenin and mutation analysis for Wnt/β-catenin-related genes (CTNNB1, APC, AXIN1 and AXIN2) in BCA (n = 34), BCAC (n = 3), ACC (n = 67) and PA (n = 31). | 29496310 | 2018 | ||||
|
0.350 | GeneticVariation | disease | BEFREE | CTNNB1 mutation was confirmed in most basal cell adenomas tested, and findings in basal cell adenocarcinoma suggest possible tumorigenic mechanisms, including alterations in PI3K and NF-κB pathways and transcriptional regulation. | 27259009 | 2016 | ||||
|
0.350 | AlteredExpression | disease | BEFREE | Although nuclear β-catenin expression may be unable to distinguish basal cell adenoma from basal cell adenocarcinoma, it should be a helpful marker in the diagnosis of basal cell adenoma. | 21323741 | 2011 | ||||
|
0.350 | Biomarker | disease | CTD_human | Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. | 15459021 | 2005 | ||||
|
0.350 | Biomarker | disease | CTD_human | Characterization of dysplastic aberrant crypt foci in the rat colon induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. | 14507667 | 2003 | ||||
|
0.350 | Biomarker | disease | CTD_human | More frequent beta-catenin gene mutations in adenomas than in aberrant crypt foci or adenocarcinomas in the large intestines of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-treated rats. | 10965019 | 2000 |